AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
The results, from a small trial of a drug called CT-388, hint that Roche could be a serious player in the weight-loss market in coming years.
The parent of Novo Nordisk is acquiring 60% ownership of Single Use Support. Elsewhere, ICER is raising questions about a PTSD drug and BioMarin is cut jobs after a pipeline review.
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year’s “Choose France” business summit. Together with the domestic Sanofi (NASDAQ: SNY), Pfizer, AstraZeneca will together invest €1.87 billion which is more than $2 billion to expand their operations in the country. AstraZeneca committed 365 million euros, which is about $394 mi
There has been several developments in the KRAS inhibitor space, shaping the KRAS inhibitors of the future.
Cancers of neuroendocrine cells, neuroendocrine tumours (NETs), commonly spread to the liver from other organs in the body.
Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
A fire broke out Thursday on the roof of a new building under construction at a Novo Nordisk manufacturing site in Kalundborg, Denmark, where the drug maker is expanding capacity for its popular diabetes and weight-loss drugs. The company’s American depositary receipts were down 1.28% in morning trading. “We are optimistic that it will not impact production timelines.”
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?